[ad_1]
Northstar Asset Management LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 35,517 shares of the company’s stock after selling 600 shares during the quarter. Johnson & Johnson makes up 1.6% of Northstar Asset Management LLC’s portfolio, making the stock its 16th biggest position. Northstar Asset Management LLC’s holdings in Johnson & Johnson were worth $6,294,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of the business. Magnolia Capital Management Ltd. raised its position in Johnson & Johnson by 0.5% in the 1st quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock worth $1,978,000 after purchasing an additional 55 shares during the last quarter. Howard Financial Services LTD. grew its holdings in Johnson & Johnson by 2.1% during the 1st quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock worth $489,000 after acquiring an additional 57 shares during the period. Capital Investment Counsel Inc grew its holdings in Johnson & Johnson by 0.8% during the 4th quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s stock worth $1,334,000 after acquiring an additional 59 shares during the period. Kwmg LLC grew its holdings in Johnson & Johnson by 2.6% during the 1st quarter. Kwmg LLC now owns 2,354 shares of the company’s stock worth $417,000 after acquiring an additional 59 shares during the period. Finally, Beaton Management Co. Inc. grew its holdings in shares of Johnson & Johnson by 0.3% in the 4th quarter. Beaton Management Co. Inc. now owns 22,250 shares of the company’s stock valued at $3,806,000 after buying an additional 60 shares during the period. Institutional investors and hedge funds own 68.78% of the company’s stock.
Wall Street Analyst Weigh In
JNJ has been the subject of several research analyst reports. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a report on Friday, July 8th. Raymond James boosted their price target on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Citigroup cut their price target on shares of Johnson & Johnson from $210.00 to $205.00 in a research report on Tuesday, May 17th. Finally, Credit Suisse Group upped their target price on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $191.29.
Insider Activity
In other news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at $12,336,803. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 78,161 shares of company stock valued at $13,895,302. Insiders own 0.35% of the company’s stock.
Johnson & Johnson Stock Up 1.5 %
Shares of JNJ opened at $178.23 on Friday. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The firm has a market cap of $468.99 billion, a P/E ratio of 24.02, a price-to-earnings-growth ratio of 3.48 and a beta of 0.63. The firm’s 50-day simple moving average is $176.76 and its 200 day simple moving average is $174.35. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.60 by $0.07. The firm had revenue of $23.43 billion for the quarter, compared to analyst estimates of $23.62 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The business’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.59 EPS. On average, analysts forecast that Johnson & Johnson will post 10.21 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th were paid a $1.13 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date of this dividend was Monday, May 23rd. This represents a $4.52 annualized dividend and a yield of 2.54%. Johnson & Johnson’s dividend payout ratio is presently 60.92%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Recommended Stories
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link
